Merck Group’s Post

A big step in realizing our strategy towards on integrated offering for viral vector manufacturing!

 🧬𝐌𝐢𝐥𝐥𝐢𝐩𝐨𝐫𝐞𝐒𝐢𝐠𝐦𝐚 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐂𝐥𝐨𝐬𝐮𝐫𝐞 𝐨𝐟 𝐌𝐢𝐫𝐮𝐬 𝐁𝐢𝐨 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧🔬 Exciting news coming from MilliporeSigma today, closing the acquisition of Mirus Bio for approximately $600 million after the completion of closing conditions. This move affirms their commitment to supporting their customers advancing cell and gene therapies throughout the life cycle, from preclinical through to commercial production. ► Sebastián Arana A., EVP & Global Head of Process Solutions stated "Mirus Bio’s advanced technology, combined with our bioprocessing expertise and broad portfolio, will enable us to deliver integrated solutions across the viral vector value chain and help meet the growing demand for these life-saving therapies.” Check out the full-press release below for more details 👇 https://lnkd.in/edjNu3JT #cellandgenetherapy #acquisition #viralvector #bioprocessing

#News: MilliporeSigma , the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million. Mirus Bio, part of Gamma Biosciences , is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®. Transfection reagents play a critical role in the production of viral vector-based gene therapies. “Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years1 and will continue to advance, with a projected growth of 30 percent until 20282,” said Matthias Heinzel, Member of the Executive Board and CEO Life Science, Merck KGaA, Darmstadt, Germany. “We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, CEO of Mirus Bio. “MilliporeSigma’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.” Read more from Morningstar 👇🏽 https://lnkd.in/eZ9RPCNe

https://lnkd.in/eUbsjPqZ Big Pharma Ramps Up Investment in Cell and Gene Therapy Pharmaceutical giants are driving the next wave of innovation in cell and gene therapy, leveraging their resources to overcome industry challenges and expand market potential. The 2024 Cell & Gene Meeting on the Mesa revealed a strong push from Big Pharma to lead this sector, bridging the gap for smaller biotech firms and addressing financing hurdles. With patents expiring and rising patient demand, these investments are set to reshape healthcare. #CellAndGeneTherapy #BigPharma #BiotechInnovation #FutureOfMedicine #GeneTherapy #HealthcareInnovation #PharmaInvestment #MeetingOnTheMesa

Thoughts on this? >> Miltenyi Biotec and Translational Health Science Institute collaborate to strengthen R&D in cell and gene therapy - Express Pharma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #biotech #pharmaceutical

🚀 The Spark of Curiosity: Our Infinite Journey of Discovery 🌟 "The creation of new knowledge starts from the spark of curiosity to seek explanations and then you find more knowledge." — David Deutsch, The Beginning of Infinity In our fast-paced world, it's easy to overlook the fundamental driver of progress: curiosity. It's this insatiable desire to understand, to question, and to explore that fuels innovation and propels us forward. Every breakthrough, every leap in technology, and every scientific discovery starts with a simple question: Why? How? What if? From these questions, we embark on a journey of exploration, uncovering new insights and expanding our horizons. David Deutsch beautifully encapsulates this endless cycle in his book, reminding us that our potential for growth is boundless. Each new piece of knowledge we gain is not an endpoint but a stepping stone to further inquiry and discovery. As we navigate our careers and personal lives, let's embrace our inner curiosity. Let’s ask more questions, seek deeper explanations, and remain open to the infinite possibilities that lie ahead. After all, the journey of knowledge is infinite, and it all begins with that first spark of curiosity. Here's to a future where we never stop learning and discovering! 🌐💡 #West #Innovation #Curiosity #Knowledge #Learning #Progress

Thoughts on this? >> Miltenyi Biotec and Translational Health Science Institute collaborate to strengthen R&D in cell and gene therapy - Express Pharma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #competitivemarketing #pharmaceutical

Ins & Outs, a #CDMO roundup brought to you by #BioProcessInsider- #ForgeBiologics appoints John Maslowski as CEO, succeeding Timothy Miller to drive growth in gene therapy manufacturing. #Veranova expands its advisory board with industry experts Rajni Aneja and MIT's Bradley Pentelute, enhancing strategic insights. #CellipontBioservices names Darren Head as CEO to steer its next growth phase in cell and gene therapy.

Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies. https://lnkd.in/eEnj2D4f

The review article entitled "Advances in Analytical Technologies for Emerging Drug Modalities and Their Separation Challenges in LC-MS Systems," published in the Journal of Chromatography A (Journal of Chromatography A 1732 (2024) 465226), describes the latest advances in LC-MS, focusing on the challenges associated with the analysis of new biotherapeutics, also known as “new modalities”. The paper outlines the growing complexity of biopharmaceutical products such as antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), and gene therapy products, which require state-of-the-art analytical methods, due to their complex structures. The review highlights the rapid development of novel LC-MS methodologies adapted for these complex modalities, including AEX-MS, RP-IP-LC-MS, HILIC-MS, and microflow-LC-MS. Each method presents unique advantages, but also specific challenges, particularly in the separation and quantification of biomolecules at low concentration. The paper highlights the importance of sample preparation, with various techniques such as enzyme digestion, denaturation, and solid-phase extraction, which are critical to enahnce sensitivity and reproducibility. This work is a comprehensive guide for researchers navigating in the complex landscape of biotherapeutics analysis, offering interesting perspectives into the current state and future directions of LC-MS technologies. Congratulations to the authors for their interesting contribution to the field!